CHML and cancer: Lung adenocarcinoma (LUAD) patient data from the Pan‐Cancer Atlas indicated that ~ 14% (70/503) of patients exhibited high CHML mRNA levels, which correlated with a decrease in overall time of survival (Fig. 2A‐B).